advanced search

Intertek Pharmaceutical Services

Intertek Melbourn provides analytical and formulation services to pharma, biotech and drug delivery, with expertise in inhalation and other dosage forms. Services include performance testing, method development/validation, stability, CMC, formulation development and clinical manufacturing.


Visit Website

Headquarters
Intertek Melbourn
Saxon Way
Melbourn
Hertfordshire
SG8 6DN
United Kingdom

Phone / Contact

T: + 1763 261 648
E: [email protected]

Connect

Intertek Melbourn, part of Intertek’s Pharmaceutical Services division,  provides product performance testing, method development/validation, stability, CMC support, formulation development and clinical manufacturing capabilities to the pharmaceutical, biotechnology and drug delivery industries.

Intertek Melbourn has specialist skills and experience in analytical testing and formulation for inhaled and intranasal products (OINDPs) as well as all other dosage forms. Its services span preformulation and formulation, analytical support, method development and validation; stability studies, stability storage, GMP batch release testing and clinical trial materials manufacturing.

Intertek Melbourn was formed when Intertek Group acquired Melbourn Scientific in 2013. The parent company, Intertek Group plc,  is headquartered in London, UK, and publicly traded on the London Stock Exchange (LON: ITRK). It has a network of more than 1,000 laboratories and offices and over 43,000 people in more than 100 countries, which deliver testing, inspection and certification solutions for its customers’ operations and supply chains across a range of industries worldwide.

Articles by Intertek Pharmaceutical Services

EXPERT VIEW
Mark Parry
TRACE ANALYTICAL CONSIDERATIONS WHEN REFORMULATING pMDIS WITH NEXT-GENERATION LOW-GWP PROPELLANT SYSTEMS
Mark Parry, John McLaughlin and Tino Otte discuss the necessary studies required to understand the nitrosamine formation and leachables profiles of new pMDI propellants with lower global warming potentials as part of the pharmaceutical industry’s drive to reduce its emissions and environmental impact.
EXPERT VIEW
Mark Parry
CONSIDERATIONS WHEN SWITCHING FROM CURRENT pMDI PROPELLANTS TO NEW LOWER-GWP PROPELLANTS
Mark Parry discusses the considerations that need to be made when switching from current pressurised metered dose inhaler propellants to new alternatives with lower global warming potential, including formulation, regulatory and analytical standpoints.
NASAL
David Ward
INTRANASAL DELIVERY OF BIOLOGIC THERAPEUTICS AND VACCINES
David Ward looks at how the nasal route of drug administration offers the potential to improve the delivery of biologics, even for very complex molecules such as antibodies – and why strategic formulation is required to make this a reality.
NASAL
David Ward
OPTIMISING NASAL DRUG PRODUCTS FOR SYSTEMIC DELIVERY
David Ward discusses the benefits of systemic nasal delivery, describes a number of formulation strategies, and explains how to optimise absorption through properly informed formulation and device selection.
PULMONARY
Mark Parry
IN VITRO BIOEQUIVALENCE – WHERE ARE WE NOW?
With a focus on bioequivalence testing in generic inhalables development, Mark Parry highlights shortcomings of aerodynamic particle size distribution and delivered dose testing, and introduces newer testing techniques.
RESPIRATORY
Chris Vernall
INTERTEK’S CENTRE OF EXCELLENCE FOR INHALED AND NASAL BIOLOGICS
Chris Vernall discusses the significance and difficulties of biologics in the inhalables sector, and how Intertek’s Centre of Excellence for Inhaled and Nasal Biologics provides valuable services for those developing products in this area.
Top